Silence Therapeutics
Logotype for Silence Therapeutics plc

Silence Therapeutics (SLN) investor relations material

Silence Therapeutics Proxy filing summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Silence Therapeutics plc
Proxy filing summary12 Nov, 2026

Executive summary

  • Definitive acquisition agreement with Merck KGaA announced October 19, 2026; closing expected in Q1 2027, subject to customary conditions.

  • Q3 2026 cash and cash equivalents were $247.7 million, including $201.3 million in gross proceeds from an August public offering; net loss was $12.4 million vs. $21.0 million in Q3 2025.

Voting matters and shareholder proposals

  • A transaction proxy statement and UK scheme explanatory statement are planned; securityholders were urged to review them and any related filings when available.

  • Completion depends in part on required shareholder approvals and sanction by the High Court of Justice of England and Wales.

Board of directors and corporate governance

  • Iain Ross signed the filing as Interim Principal Executive Officer and Chairman of the Board.

  • Directors, certain executive officers and other employees may be deemed participants in the transaction-related proxy solicitation; additional interest details are expected in the transaction proxy statement.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Silence Therapeutics earnings date

Logotype for Silence Therapeutics plc
Q4 202626 Feb, 2027
Silence Therapeutics
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next Silence Therapeutics earnings date

Logotype for Silence Therapeutics plc
Q4 202626 Feb, 2027

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

Silence Therapeutics plc is a biotechnology company that focuses on the discovery and development of therapeutic molecules using RNA interference (RNAi) technology. The company’s proprietary mRNAi GOLD platform is designed to develop short interfering RNA (siRNA) therapies that target and silence specific genes associated with various diseases, particularly in the liver. Silence Therapeutics is involved in developing treatments for cardiovascular conditions, hematological disorders, and rare diseases. Their leading product candidates include Zerlasiran (SLN360) for cardiovascular disease and Divesiran (SLN124) for hematological conditions. Silence Therapeutics plc is headquartered in London, United Kingdom, and its shares are listed on the NASDAQ.